Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

In this case report, a patient with ankylosing spondylitis and alopecia areata who used a combination of baricitinib and golimumab experienced hair regrowth without adverse effects, but the efficacy of this treatment combination remains unestablished according to the researchers.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

In a mouse model of infected burns, this study found that treatment with recombinant fusion peptide EK significantly decreased Pseudomonas aeruginosa colony count and improved wound healing rates compared to controls.

This case report describes how anifrolumab, used beyond trial-eligible populations, led to significant clinical and serological recovery in a 45-year-old woman with organ-threatening systemic lupus erythematosus complicated by infection and resistant to conventional treatments like cyclophosphamide and rituximab.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

In this case report, researchers detailed the clinical management and positive outcome of a 62-year-old woman with catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, highlighting the potential effectiveness of Eculizumab in achieving disease remission and maintaining stability over 18 months.

This study found that a combination of natural compounds (escin, bromelain, ginkgo biloba, and sage miltiorrhiza) reduced platelet adhesion to activated endothelium in laboratory settings by inhibiting adhesion molecule transcription and reducing pro-inflammatory cytokines, potentially preventing initial steps of the coagulation cascade.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study found that the newly developed transdermal oil body microgel emulsion (OBEME) improved wound healing in mice by enhancing skin permeability, reducing inflammation, and promoting new blood vessel formation and re-epithelialization.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

The new cream is safe and effective for mild to moderate atopic dermatitis.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.

This study reports that 14 of 19 patients with erythema nodosum leprosum had C3 deposits in vessel walls when examined using direct immunofluorescence.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.